Dwight Evans is not generating headlines this week. Zero Google News stories in the last 24 hours. The only social chatter attached to his name is a baseball card collector on Bluesky who got lucky with a signed copy of an autobiography — wrong Dwight Evans, different sport entirely. But Evans the congressman, Philadelphia's representative in the House, has been busy in a different way: five stock sales in 90 days, a healthcare-sector sale that bumps against his committee jurisdiction, and a trading record that is, by any honest read of the data, a scorched-earth run of bad timing.
The Quiet Week, and the Not-Quiet Portfolio
When a member of Congress generates no press coverage for 24 hours, one of two things is true: they're doing their job with admirable discretion, or they're simply not doing much that anyone finds interesting. Evans's floor record this week suggests the former, at least by volume. On May 20 alone, he voted Yea on the American Access to Banking Act, the Community Bank Deposit Access Act of 2025, the Keeping Deposits Local Act, and the Fiscal Year 2025 Veterans Affairs Major Medical Facility Authorization Act. That's four bills in one afternoon. On May 21, he voted Nay on both the Veterans 2nd Amendment Protection Act and the Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act — both passed anyway.
Productive floor work. What Blind Trust tracks is what happens on the other side of the ledger.
Five Sales. No Buys.
Per the disclosure filings, Evans has reported five stock sales since late March and zero purchases. The full list:
- March 24, 2026: Sold Micron Technology (MU), 5K–$50K
- May 7, 2026: Sold Intel (INTC), K–5K
- May 7, 2026: Sold Quanta Services (PWR), K–5K
- May 7, 2026: Sold Thermo Fisher Scientific (TMO), K–5K
- May 11, 2026: Sold American Tower (AMT), K–5K
Semiconductor infrastructure, chip manufacturing, power grid services, life sciences instrumentation, cell tower REITs. The one common thread: Evans was moving out, not in.
The disclosure ranges are wide enough that total liquidation could be anywhere from roughly 9,000 to $95,000. Members report ranges, not exact amounts. The public gets a blurry picture and has to squint to read it.
The Alpha Record: 0-for-8
Across 8 scored trades in the full tracked sample, Evans is 0 for 8 on 30-day alpha versus the S&P 500. The mean 30-day alpha across all scored trades sits at negative 5.7%. His best performer, the May 11 AMT sale, posted an alpha of exactly 0.0%. His worst, the March 24 Micron sale, posted negative 14.1% alpha in the 30 days following the trade.
In every scored case, the market outperformed (or matched) the position Evans exited. He sold, and then the stock kept doing better than the index — on average, by 5.7 points. The three worst:
- MU (sold March 24): negative 14.1% alpha over 30 days
- TMO (sold May 7): negative 7.8% alpha over 30 days
- PWR (sold May 7): negative 7.7% alpha over 30 days
A 0-for-8 record could be bad luck. It could be an advisor's systematic de-risking strategy. The record doesn't say. What it doesn't do is tell you anything about intent, information, or skill.
The One Trade That Has a Committee Angle
Evans sits on the House Committee on Ways and Means, including its Health subcommittee — the committee with jurisdiction over Medicare, Medicaid, and the tax treatment of healthcare spending. One of the most consequential perches in the House for anyone paying attention to the life sciences sector.
On May 7, Evans sold Thermo Fisher Scientific, a medical instruments and laboratory equipment company whose revenue is deeply tied to the kind of government health spending that Ways and Means shapes. The sale was K–5K, per the Blind Trust disclosure record. Thermo Fisher outpaced the index by 7.8 points in the month after he exited.
Evans sold. He has committee jurisdiction over healthcare. Thermo Fisher is a healthcare company. The interpretation of those three facts belongs to the reader.
Members are required to disclose. They are not required to divest, recuse, abstain, or explain themselves.
Banking Bills, No Banking Stocks
Evans voted for three separate banking access bills on May 20 — the American Access to Banking Act, the Community Bank Deposit Access Act of 2025, and the Keeping Deposits Local Act — all of which passed. Market relevance scores on all three sit above 80 out of 100.
His committee assignments are Ways and Means, not Financial Services. Banking regulation lives at Financial Services. These floor votes don't carry a committee-oversight angle for Evans. He voted on them the same way 400 other members did: as a floor participant, not as an overseer.
He holds no banking stocks. Five sales, no purchases, none of the names are in the financial sector. The portfolio story and the floor vote story don't intersect.
The Full Picture
What Blind Trust tracks is the financial record alongside the legislative one. The financial record here has one clean narrative: consistent selling across five positions spanning two months, a 0-for-8 alpha record across the full scored sample, and one sale with a committee-jurisdiction overlap that the public record documents but doesn't explain.
The social media footprint this week is a retired Red Sox right fielder getting autograph credit he didn't seek. The congressional footprint is five sell orders and eight trades that underperformed the market every time they were scored.
The full record is public. Make of it what you make of it.